Prophylaxis of Candida Infections

Also known as: Prophylaxis of Candida infection / Candida infections / Candida infection / Candida / Candidas / Candida species / Candidal infection NOS / Moniliasis monilia / Monilial infection / Thrush NOS / Moniliasis NOS / Monilia NOS / Moniliasis / Candida NOS / Candidiasis of unspecified site / Candidiasis NOS / Candidiasis

DrugDrug NameDrug Description
DB00362AnidulafunginAnidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
DB00520CaspofunginCaspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
DB01099FlucytosineA fluorinated cytosine analog that is used as an antifungal agent.
DB01141MicafunginMicafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
DB01263PosaconazolePosaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.
DrugDrug NamePhaseStatusCount
DB13959Medium-chain triglycerides1Recruiting1
DB00681Amphotericin B4Unknown Status1
DB12553FluocinoloneNot AvailableCompleted1
DB14224Lactobacillus reuteriNot AvailableCompleted1
DB00646NystatinNot AvailableCompleted1
DB09536Titanium dioxideNot AvailableNot Yet Recruiting1